AbbVie

The study is designed to examine the safety and efficacy of a drug that targets the protein tau in the brains of people with Alzheimer’s disease. Research has shown that cognitive decline in patients with Alzheimer’s disease may relate to levels of abnormal tau protein in the brain. You may be eligible for this study if you have been diagnosed with Mild Cognitive Impairment (MCI) or Dementia due to Alzheimer’s Disease.

 

The study is looking for volunteers who are:

  • Between the ages of 55-85
  • Able to have an MRI scan
  • A patient who has been diagnosed with Early Alzheimer’s Disease

 

For more information, please contact Parisa Oviedo, Study Coordinator.

 

Download Flyer: